NCT00213720

Brief Summary

Objective: To determine if the treatment of subclinical hyperthyroidism will reduce the rate of atrial fibrillation, the main complication of this condition.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
145

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Aug 2005

Longer than P75 for all trials

Geographic Reach
1 country

21 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2005

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

September 13, 2005

Completed
8 days until next milestone

First Posted

Study publicly available on registry

September 21, 2005

Completed
14.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2019

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2020

Completed
Last Updated

September 29, 2020

Status Verified

August 1, 2019

Enrollment Period

14.3 years

First QC Date

September 13, 2005

Last Update Submit

September 25, 2020

Conditions

Keywords

Hyperthyroidismatrial fibrillationquality of liferadioiodine treatment

Eligibility Criteria

Age50 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

patients referred to tertiary hospitals for advice on thyroïd disease

You may qualify if:

  • Men and women aged 50 and greater
  • Isolated decreased thyroid-stimulating hormone (TSH) with normal FT4 and FT3 levels

You may not qualify if:

  • Iodide overload
  • Non sinusal heart rhythm
  • Severe heart disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (21)

Patrick Roger

Bordeaux, France

Location

Philippe Thiéblot

Clermont-Ferrand, France

Location

Jean-Marcel Brun

Dijon, France

Location

Jean-Louis Wemeau

Lille, France

Location

Marie-Pierre Teissier

Limoges, France

Location

Jacques Orgiazzi

Lyon, France

Location

Bernard Conte-Delvox

Marseille, France

Location

CH de Montbrison

Montbrison, 42605, France

Location

Jacques Bringer

Montpellier, France

Location

Marc Klein

Nancy, France

Location

Michel Rodier

Nîmes, France

Location

Laurence Leenhardt

Paris, France

Location

Richard Marechaud

Poitiers, France

Location

Brigitte Delemer

Reims, France

Location

Claire Schvartz

Reims, France

Location

Jean-Marc Kuhn

Rouen, France

Location

Bruno Estour

Saint-Etienne, France

Location

Centre Paul Strauss

Strasbourg, 67000, France

Location

Hopitaux Universitaires de Strasbourg

Strasbourg, France

Location

Philippe Caron

Toulouse, France

Location

Pierre Lecomte

Tours, France

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

serum

MeSH Terms

Conditions

Atrial FibrillationHyperthyroidism

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsThyroid DiseasesEndocrine System Diseases

Study Officials

  • Bernard Goichot, MD

    Hopitaux Universitaires de Strasbourg

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 13, 2005

First Posted

September 21, 2005

Study Start

August 1, 2005

Primary Completion

November 1, 2019

Study Completion

January 1, 2020

Last Updated

September 29, 2020

Record last verified: 2019-08

Locations